Autres langues Oncolytics Biotech Inc.

Actions

ONC

CA6823108759

Marché Fermé - Toronto S.E. Autres places de cotation 21:59:31 01/05/2024			Varia. 5j.	Varia. 1 janv.
1,54 ^CAD	+0,65%		+4,76%	-13,97%

11/04	Oncolytics Biotech Inc. annonce la soumission d'une demande de réunion de type C à la FDA	CI
08/03	RBC réitère ses perspectives positives à l'égard d'Oncolytics -- Maintient l'objectif de 6 $ et la cote surperformance/risque spéculatif	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights	01/05
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights	30/04
Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	26/04
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	25/04
Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K	12/04
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	12/04
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	11/04
Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	11/04
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	11/04
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	11/04
Oncolytics Biotech to participate in a Panel Presentation at Canaccord Genuity s Horizons in Oncology Virtual Conference	03/04
RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating	08/03
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain	07/03
Oncolytics Biotech Brief: Q4 Net loss for the fourth quarter of 2023 was $3.9 million	07/03
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms	07/03
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning	06/03
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	05/03
Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	05/03
Oncolytics Biotech Brief: Says Filed Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Oncolytics Biotech Inc.

Actions

ONC

CA6823108759

Autres langues

Filtres